$71.70
-0.27-0.38%
At close: Aug 14, 5:00 PM EST
$71.70
N/A
After Hours: Aug 14, 4:00 PM EST
PTC Therapeutics Inc
PTCTNASDAQ
M&A: Sangamo Therapeutics announced it will sell assets to PTC Therapeutics (PTCT) on Wednesday, August 12, 2026
PTC Therapeutics Earnings & Forecasts
PTC Therapeutics (PTCT) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
PTC Therapeutics Guidance
PTC Therapeutics (PTCT) last issued guidance on July 30, 2026 for fiscal year 2026. The company guided revenue in the range of $1.18B - $1.28B for the period.
Compared to prior guidance, PTC Therapeutics raised its revenue forecast from a prior range of $1.08B - $1.18B.
PTC Therapeutics has issued 23 guidance updates between October 27, 2022 and July 30, 2026. During this period, the company raised its outlook 8 times and lowered it 6 times, providing investors with insight into management's evolving expectations.
Recent Earnings Results
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.31 | $-0.41 | $-0.33 | $-1.14 |
| Actual | $0.92 | $-0.03 | $-1.67 | $0.20 |
| Surprise | +196.8% | +92.7% | -406.1% | +117.5% |
| Revenue | ||||
| Estimate | $292.7M | $227.5M | $295.4M | $175.5M |
| Actual | $360.5M | $272.6M | $164.7M | $211.0M |
| Surprise | +23.2% | +19.8% | -44.3% | +20.2% |
Analyst Estimates — Forward PeriodsSource: Wall Street consensus
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.28 | $0.20 | $0.07 | $0.16 |
| Revenue | ||||
| Consensus | $309.6M | $323.2M | — | — |
